<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03486080</url>
  </required_header>
  <id_info>
    <org_study_id>REC-DUT-002</org_study_id>
    <nct_id>NCT03486080</nct_id>
  </id_info>
  <brief_title>Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Dutogliptin in Combination With Filgrastim in Early Recovery Post-Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recardio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recardio, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of
      Dutogliptin in Combination with Filgrastim in Early Recovery Post-Myocardial Infarction
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dutogliptin 60 mg administered by twice daily subcutaneous (SC) injection for 14 days in
      combination with a fixed standard dose of filgrastim (10 µg/kg) administered SC daily for 5
      days. This study will be conducted in adults with ST-elevation myocardial infarction (STEMI)
      with successful revascularization following percutaneous coronary intervention (PCI) and
      stent implantation.

      Primary Objective

      • To evaluate the safety and tolerability of dutogliptin in combination with filgrastim in
      subjects with STEMI compared with placebo

      Secondary Objectives

        -  To assess preliminary efficacy of dutogliptin in combination with filgrastim in subjects
           with STEMI compared with placebo as determined by cardiac magnetic resonance imaging
           (cMRI)

        -  To determine the pharmacokinetics (PK) of dutogliptin in a subset of the study
           population

        -  To establish the pharmacodynamics (PD) of dutogliptin (plasma DPP4 activity) in a subset
           of the study population

      Exploratory Objectives

        -  To examine the effects of dutogliptin in combination with filgrastim on:

        -  Change from baseline in plasma stromal cell-derived factor (SDF)-1a levels

        -  Change from baseline in plasma biomarkers, including N-terminal pro-b-type natriuretic
           peptide (NT-proBNP) and high sensitivity troponin
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2018</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Blinded placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Safety assessment of the number of Grade 3 and 4 treatment emergent AEs or serious AEs (SAEs) as assessed by CTCAE v4.0.AEs (SAEs) as assessed by CTCAE v4.0.</measure>
    <time_frame>90 days</time_frame>
    <description>Assess the tolerability of a combination of dutogliptin and filgrastim</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular efficacy LVEF</measure>
    <time_frame>90 days</time_frame>
    <description>Left ventricular ejection fraction (%) by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular efficacy LVESV</measure>
    <time_frame>90 days</time_frame>
    <description>Left ventricular end systolic volume (mL) by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular efficacy LVEDV</measure>
    <time_frame>90 days</time_frame>
    <description>Left ventricular end diastolic volume (mL) by MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular tissue damage reduction</measure>
    <time_frame>90 days</time_frame>
    <description>Infarct size (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular LFM</measure>
    <time_frame>90 days</time_frame>
    <description>Left ventricular mass (mm2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular motion</measure>
    <time_frame>90 days</time_frame>
    <description>Regional wall motion (mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK)</measure>
    <time_frame>14 days</time_frame>
    <description>Assess the systemic exposure (dutogliptin AUC) of s.c. administered dutogliptin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD)</measure>
    <time_frame>14 days</time_frame>
    <description>Assess the PD effects (plasma DPP4 activity) of s.c. administered dutogliptin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Acute Myocardial Ischemia</condition>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Dutogliptin/filgrastim combination</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Twice daily SC injections of 60 mg dutogliptin tartrate for 14 days in combination with 10 µg/kg filgrastim injectable product for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Twice daily dutogliptin SC placebos for 14 days in combination with matching filgrastim SC placebos for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutogliptin Tartrate</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Dutogliptin/filgrastim combination</arm_group_label>
    <other_name>dutogliptin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim Injectable Product</intervention_name>
    <description>Active treatment</description>
    <arm_group_label>Dutogliptin/filgrastim combination</arm_group_label>
    <other_name>filgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>placebo control</description>
    <arm_group_label>Placebo control</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 1. Male or female born between 1933 and 2000.

          2. Body weight &lt;96 kg (212 lb).

          3. Able to provide written informed consent, including signing and dating the informed
             consent form (ICF).

          4. Diagnosis of STEMI (defined as new ST-segment elevation at the J point of at least 2
             continuous leads of &gt;2 mm [0.2 mV] in men or &gt;1.5 mm [0.1 mV] in women in leads V2 and
             V3 OR &gt;1 mm in any other contiguous precordial leads or the limb leads [for both men
             and women]) with PCI (bare metal or drug-eluting stent) and Thrombolysis in Myocardial
             Infarction flow grade 2 or 3 occurring &gt;2 hours and &lt;24 hours after symptom onset.

          5. LVEF ≤45% obtained by cECHO performed within 36 hours post-stent placement.

          6. Receiving standard medical therapy for post-MI treatment, according to local
             procedures and Principal Investigator discretion

          7. Female subjects of childbearing potential must have a negative serum pregnancy test at
             Screening and an additional negative urine pregnancy test prior to the first dose of
             IMP unless regulated differently by national legislation.

          8. Sexually active female subjects of childbearing potential (i.e., women who are not
             postmenopausal or who have not had a bilateral oophorectomy, hysterectomy, or tubal
             ligation) and all male subjects (who have not been surgically sterilized by vasectomy)
             must agree to use effective contraception during the study.

        Exclusion criteria

          1. Previous MI prior to Screening.

          2. Complex peri/post-MI clinical course, including arrhythmias, cardiogenic shock,
             pulmonary edema requiring mechanical ventilation, or requirement for vasopressor
             medications.

          3. Significant pre-existing cardiomyopathy with known LVEF ≤45% or moderate to severe
             mitral or aortic valvular disease.

          4. Amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or
             constrictive pericarditis.

          5. Existing heart transplant.

          6. Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.

          7. Uncontrolled hypertension (systolic &gt;180 mmHg or diastolic &gt;120 mmHg).

          8. Treatment with any DPP4 inhibitors (e.g., alogliptin, linagliptin, vildagliptin,
             saxagliptin, sitagliptin) or G-CSF medication (e.g., filgrastim, lenograstim,
             pegfilgrastim, lipegfilgrastim) within 4 months prior to Randomization.

          9. Contraindication to treatment with filgrastim, including known allergy to filgrastim
             or other G-CSF medication.

         10. Anemia defined as hemoglobin &lt;9 g/dL prior to Randomization.

         11. Thrombocytosis (platelets &gt;500 k/µL).

         12. Known positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus
             (HIV).

         13. Alanine aminotransferase (ALT) concentrations &gt;3 times the upper limit of normal (ULN)
             or bilirubin &gt;2 x ULN prior to Randomization, according to local laboratory
             assessments.

         14. History of cirrhosis and Child-Pugh score B or C.

         15. Current fever greater than 101.4 °F (38.6 °C) or recent systemic infection within 2
             weeks prior to Randomization.

         16. Contraindication to cMRI procedure, including prior implantable cardioverter
             defibrillator placement, known reaction to gadolinium, claustrophobia,
             non-MRI-compatible, cochlear implant, morbid obesity, or presence of ferromagnetic
             material including shunts, shrapnel, penile prostheses, or blood vessel coil.

         17. Pregnant, planning to become pregnant, or nursing female subjects.

         18. Autoimmune disease requiring immunosuppressive therapy or chronic steroid treatment &gt;5
             mg/day prednisolone or equivalent.

         19. Significant renal impairment defined as estimated glomerular filtration rate &lt;45
             mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration equation.

         20. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12
             months (subjects with a history of malignancy who have undergone curative resection or
             otherwise not requiring treatment for at least 12 months prior to Screening with no
             detectable recurrence are allowed).

         21. Malignant hematological disease, i.e., chronic myeloid leukemia or myelodysplastic
             syndrome.

         22. History of cerebrovascular accident or transient ischemic attack in the past 6 months.

         23. History of pneumonia in the last 4 weeks.

         24. History of any significant medical or psychiatric disorder that in the opinion of the
             investigator would make the subject unsuitable for participation in the study.

         25. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
             longer) or treatment with an investigational biologic drug within 6 weeks prior to
             randomization.

         26. Participation in another concurrent clinical trial involving a therapeutic
             intervention (participation in observational studies and/or registry studies is
             permitted).

         27. Unable or unwilling to comply with the requirements of the study.

         28. Subject and/or an immediate family member is an employee of the investigational site
             directly affiliated with this study, the sponsor or the contract research
             organization.

         29. Considered by the investigator to be unsuitable to participate in the study for any
             other reason.

         30. Persons who are in an institution as a result of an administrative or judicial order,
             or soldiers.

         31. History of alcohol or drug abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman Schenk, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Recardio, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roman Schenk, MD</last_name>
    <phone>415 707-0592</phone>
    <email>rs@recardio.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Darrell Nix, Ph.D.</last_name>
    <phone>415-429-5991</phone>
    <email>dn@recardio.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center, Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Pozun</last_name>
      <phone>916-533-1603</phone>
      <email>Melissa.Pozun@veristat.com</email>
    </contact>
    <investigator>
      <last_name>Timothy Henry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Clinical Medical Group</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Pozun</last_name>
      <phone>916-533-1603</phone>
      <email>Melissa.Pozun@veristat.com</email>
    </contact>
    <investigator>
      <last_name>Phillip Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital-Minneapolis Heart Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Pozun</last_name>
    </contact>
    <contact_backup>
      <phone>916-533-1603</phone>
      <email>Melissa.Pozun@veristat.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jay H Travese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical department of Cardiology</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Dirk von Lewinski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical department of Cardiology</name>
      <address>
        <city>Linz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Regina Steringer-Mascherbauer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Algemeen Stedelijk Ziekenhuis Aalst</name>
      <address>
        <city>Aalst</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Ian Buysschaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zna Middelheim</name>
      <address>
        <city>Antwerp</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Paul Vermeersch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic Tokuda Hospital</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Valeri Gelev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Acibadem CityClinic</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Ivo Petrov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I.Pirogov</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Mariya Milanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Military Hospital</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Róbert Gábor Kiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Városmajori Szív- és Érgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Béla Merkely, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Kardiológiai és Szívsebészeti Klinika</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Istvan Édes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Oktatókórház</name>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Geregly Nagy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PTE ÁOK Szívgyógyászati Klinika</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Iván Horváth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zala Megyei Szent Rafael Kórház</name>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Géza Lupkovics, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Geleen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
    </contact>
    <contact_backup>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bas Kietselaer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Pim Van der Harst, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUMC</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Arnoud van't Hof, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Peter Smits, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zuyderland medisch centrum</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Bas Kietselaer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Isala</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Jorik Timmer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nicolaus Copernicus University</name>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Jacek Kubica, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SPS Szpital Zachodni</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Górnośląskie Centrum Kardiologii Szpital w Ochojcu</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
    </contact>
    <contact_backup>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact_backup>
    <investigator>
      <last_name>Wojciech Wojakowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krakowski Szpital Specjalistyczny im. Jana Pawla II, Oddzial Kliniczny Chorob Serca i Naczyn ul. Pradnicka 80</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Piotr Musialek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Wojewódzki im. Papieża Jana Pawła II</name>
      <address>
        <city>Zamość</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
    </contact>
    <contact_backup>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact_backup>
    <investigator>
      <last_name>Andrzej Kleinrok, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny Uniwersytetu Medycznego w Lodzi ul. Pomorska 251</name>
      <address>
        <city>Łódź</city>
        <zip>92-213</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adam Mickiewicz</last_name>
      <phone>0048605300571</phone>
      <email>adam.mickiewicz@altiora-cro.net</email>
    </contact>
    <investigator>
      <last_name>Pawel Ptaszynski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Sharp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubille National Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>Keith Oldroyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Veronika Garus</last_name>
      <phone>+49 (0)8141 8891523</phone>
      <email>veronika.garus@sacura-cro.com</email>
    </contact>
    <investigator>
      <last_name>John Greenwood, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://recardio.eu</url>
    <description>Recardio, Inc. Homepage</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2018</study_first_submitted>
  <study_first_submitted_qc>April 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2018</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

